Plasma-Safe-SeqS
Biomarker detection
Sysmex Inostics empowers accurate low-frequency biomarker detection from a simple blood draw.
- Detect earlier
- Monitor easily
- Partner confidently
- Leader in ultra-sensitivity
0.03-0.05%
Our lab runs blood-based biomarker analyses to detect, track, and monitor relevant mutations in circulating tumor DNA (ctDNA) at low levels (0.03-0.05%) with high specificity.
Expedite your clinical studies and uncover deeper insights into therapy response.
Our video presentation illustrates how our Plasma-Safe-SeqS NGS technology can detect clinically relevant mutations in ctDNA as low as 0.03%* mutant allele frequency (MAF). Plasma-Safe-SeqS ensures reliable molecular information for real-time therapy selection as well as monitoring of tumor response.
*For input of 20,000 genomic equivalents